Also known as Toradol, Acular, Acuvail, and Sprix
Ketorolac or ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) in the family of heterocyclic acetic acid derivatives, often used as an analgesic. Ketorolac was discovered in 1989 by Syntex Corp. (now Roche Bioscience, which is a wholly owned subsidiary of Roche holding Ltd., the parent company of Roche). It was approved by FDA on 30 November 1989 and introduced as Toradol by Syntex. The ophthalmic (i.e., eye-drop) form was approved by FDA on 9 November 1992 and was introduced as Acular eye drops by Allergan under license from Syntex. An intranasal formulation of ketorolac tromethamine was approved by FDA on 14 May 2010 and introduced as Sprix Nasal Spray by Daiichi Sankyo for short-term management of moderate to moderately severe pain requiring analgesia at the opioid level. In India it is available as Ketanov by Ranbaxy, which is owned by Daiichi Sankyo.Source: Wikipedia
DEA Class 2 meaning a high potential for abuse, less abuse potential than Schedule I drugs, with use potentially leading to severe psychological or physical dependence.
Estimated Total Cost: $47.36 for an average of 21 days supply
Patients are most commonly prescribed ketorolac to treat side pain, kidney stone, meckel diverticulum, and neck weakness.